Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 13, Art. 17 (pp. 207-217)    |    2012       
»

The PROGINS allele of the progesterone receptor (PGR) gene is associated with the increased risk of breast cancer in Western Siberian region of Russia
Pechkovskiy E. V.1; Weiner A. S.1,2; Boyarskikh U. A.1; Biltueva Ju. A.1; Selezneva I. A.3; Sinkina T. V.3; Lazarev A. F.3; Petrova V. D.3; Filipenko M. L.1

1 Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, 630090

2 Novosibirsk State University, Novosibirsk, 630090

3 Altai Branch of Russian N.N. Blokhin Cancer Research Centre, Barnaul, 656049



Brief summary

Breast cancer (BC) is the most incident cancer among women. Genetic polymorphism of progesterone receptor may be involved in the etiology of BC. In the present study we aimed to investigate the association of polymorphism rs1042838 (PROGINS allele) of PGR gene with the risk of BC in the West Siberian Region of Russia. We analyzed the case (644 BC women) and the control (466 women) groups. Allele T (OR = 1.30; p = 0.02) and genotype Т/Т (OR = 2.19; p = 0.03) were associated with the increased risk of BC. After stratification of the case group according to PGR expression status, we revealed an association only in the subgroup of patients with low level of PGR expression (for allele T: OR = 1.52; p = 0.006; for genotype Т/Т: OR = 2.67; p = 0.03).


Key words

breast cancer, progesterone receptor, PROGINS allele, association, Russian population





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Willems P. J. Susceptibility genes in breast cancer: more is less? // Clinical Genetics - 2007 - Vol.72 - №6 - P.493-496.


2. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease // Lancet - 2001 - Vol.358 - №9291 - P.1389-1399.


3. Ruan W., Monaco M. E., Kleinberg D. L. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action // Endocrinology - 2005 - Vol.146 - №3 - P.1170-1178.


4. Graham J. D., Clarke C. L. Physiological action of progesterone in target tissues // Endocr Rev - 1997 - Vol.18 - №4 - P.502-519.


5. Conneely O. M., Lydon J. P. Progesterone receptors in reproduction: functional impact of the A and B isoforms // Steroids - 2000 - Vol.65 - №10-11 - P.571-577.


6. Scarpin K. M., Graham J. D., Mote P. A. et al. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression // Nucl Recept Signal - 2009 - Vol.7 - P.e009.


7. Mulac-Jericevic B., Lydon J. P., Demayo F. J. et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform // Proc Natl Acad Sci U S A - 2003 - Vol.100 - №17 - P.9744-9749.


8. Chang K. J., Lee T. T., Linares-Cruz G., et al.. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo // Fertil Steril - 1995 - Vol.63 - №4 - P.785-791.


9. Foidart J. M., Colin C., Denoo X., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells // Fertil Steril - 1998 - Vol.69 - №5 - P.963-969.


10. Gompel A., Malet C., Spritzer P., et al. Progestin effect on cell proliferation and 17 betahydroxysteroid dehydrogenase activity in normal human breast cells in culture // J Clin Endocrinol Metab - 1986 - Vol.63 - №5 - P.1174-1180.


11. Franke H. R., Vermes I. Differential effects of progestogens on breast cancer cell lines // Maturitas - 2003 - Vol.46 Suppl 1 - P.S55-58.


12. Mauvais-Jarvis P., Kuttenn F., Gompel A. Antiestrogen action of progesterone in breast tissue // Breast Cancer Res Treat - 1986 - Vol.8 - №3 - P.179-188.


13. Van Bogaert L. J. Effect of hormone on human mammary duct in vitro // Horm Metab Res - 1978 - Vol.10 - №4 - S.337-340.


14. Cappelletti V., Miodini P., Fioravanti L. et al. Effect of progestin treatment on estradioland growth factor-stimulated breast cancer cell lines // Anticancer Res - 1995 - Vol.15 - №6B - P.2551-2555.


15. Chen W. Y., Hankinson S. E., Schnitt S. J., et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma // Cancer - 2004 - Vol.101 - №7 - P.1490-1500.


16. Colditz G. A., Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study // Am J Epidemiol - 2000 - Vol.152 - №10 - P.950-964.


17. Ross R. K., Paganini-Hill A., Wan P. C. et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin // J Natl Cancer Inst - 2000 - Vol.92 - №4 - P.328-332.


18. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study // Lancet - 2003 - Vol.362 - №9382 - P.419-427.


19. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study // Breast Cancer Res Treat - 2008 - Vol.107 - №1 - P.103-111.


20. Romano A., Delvoux B., Fischer D. C. et al. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone // J Mol Endocrinol - 2007 - Vol.38 - №1-2 - P.331-350.


21. Romano A., Lindsey P. J., Fischer D. C., et al. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer // Gynecol Oncol - 2006 - Vol.101 - №2 - P.287-295.


22. Agoulnik I. U., Tong X. W., Fischer D. C., et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk // J Clin Endocrinol Metab - 2004 - Vol.89 - №12 - P.6340-6347.


23. Pooley K. A., Healey C. S., Smith P. L., et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach // Cancer Epidemiol Biomarkers Prev - 2006 - Vol.15 - №4 - PS.675-682.


24. Johnatty S. E., Spurdle A. B., Beesley J., et al. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies // Breast Cancer Res Treat - 2008 - Vol.109 - №1 - P.91-99.


25. Ralph D. A., Zhao L. P., Aston C. E., et al. R. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk // Cancer - 2007 - Vol.109 - №10 - P.1940- 1948.


26. Gaudet M. M., Milne R. L., Cox A., et al. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium // Cancer Epidemiol Biomarkers Prev - 2009 - Vol.18 - №5 - P.1610-1616.


27. Fernandez L. P., Milne R. L., Barroso E., et al. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study // Int J Cancer - 2006 - Vol.119 - №2 - P.467-471.


28. Pearce C. L., Hirschhorn J. N., Wu A. H., et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis // J Natl Cancer Inst - 2005 - Vol.97 - №1 - P.51-59.


29. Wang-Gohrke S., Chang-Claude J., Becher H., et al. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50 // Cancer Res - 2000 - Vol.60 - №9 - P.2348-2350.


30. De Vivo I., Hankinson S. E., Colditz G. A. et al. The progesterone receptor Val660-->Leu polymorphism and breast cancer risk // Breast Cancer Res - 2004 - Vol.6 - №6 - P.R636-639.


31. Spurdle A. B., Hopper J. L., Chen X., et al. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women // Cancer Epidemiol Biomarkers Prev - 2002 - Vol.11 - №5 - P.439-443.


32. Fabjani G., Tong D., Czerwenka K., et al. Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women // Breast Cancer Res Treat - 2002 - Vol.72 - №2 - P.131-137.



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100